Relaxation of CBD Restriction Sparks Controversy

THC Global Group Limited embraces an interim Therapeutic Goods Administration (TGA) decision to down schedule cannabidiol (CBD) medicines to Schedule 3 to allow easier access of low-dose CBD without prescriptions.

By Judy Ya-Hsuan Lin

THC Global’s Southport Facility is one of the world’s largest pharmaceutical GMP cannabis manufacturing facilities. Because they own Crystal Mountain, a fast-growing hydroponics equipment wholesaler, they can supply wholesalers and retailers in Europe and North America’s rapidly expanding cannabis sector. The CBD market analysis company Brightfield Group predicted that the cannabis industry’s value would hit 22 billion by 2022. Although the down-scheduling ensures a well-documented safety profile, higher accessibility and better affordability to patients, the TGA decision sparks controversy over two parties holding different opinions on the expanding use of CBD.

The THC decision to expand CBD legalizes many activities and conveniences in daily life, but limited clinical evidence demonstrates the extent of therapeutic effectiveness and safety for individuals and patients. Thus, the decision poses potential suspicion. Zsolt Csonka, the founder of Adriaen Block restaurant located in Astoria, New York, uses CBD-contained concomitants in his dishes to optimize customers’ tasting experience.

Besides, he shared his experience that it usually takes 4-5 shots of Whiskey for people to feel relaxed but only two shots containing CBD to impose the same effect. Dr. Chris Freeman, the Pharmaceutical Society of Australia national president, told the Australian Journal of Pharmacy an opposing opinion. He is concerned about the lack of clinical evidence of low-dose CBD’s therapeutic efficacy for patients and the current absence of enough information to ensure patients access these medicines appropriately.

Related Article: Weekly in Asia（0414-0420）

References:

https://www.proactiveinvestors.com.au/companies/news/928601/thc-global-welcomes-interim-tga-decision-to-down-schedule-cbd-medicines-to-allow-pharmacy-access-without-prescription-928601.html

Related posts:

Spotlight: Cannabidiol (CBD) Based Medication Heralds New Promise in Neurological Therapies Marijuana for Medical Use Increases the Risk of Cannabis Use Disorder The FDA Issued its First Formal Warning to Companies Selling Delta-8 THC Products Cooperation of Two Chinese Pharma Launched Massive Clinical Trials Abroad

Author

Judy Ya-Hsuan Lin

Success is the ability to go from one failure to another with no loss of enthusiasm.

Related Post

R&D

Scientists Uncover More Evidence of CBD’s Effect on Epileptic Seizures in Children

2023-02-18

Special

The FDA Issued its First Formal Warning to Companies Selling Delta-8 THC Products

2022-05-05

Biotech

MGC Pharmaceuticals Enters Partnership with Sciensus Rare for Distribution of Cannabinoids to Treat Refractory Epilepsy, Dementia and Alzheimer’s in the EU and UK

2022-04-05